[
  {
    "ts": null,
    "headline": "PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.",
    "summary": "This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.",
    "url": "https://finnhub.io/api/news?id=d9924bfb15be4a412c5d30ffc3c153fb65db609d6f0526759c3ece67141e5e6e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735205436,
      "headline": "PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.",
      "id": 132164310,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/832255342/image_832255342.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.",
      "url": "https://finnhub.io/api/news?id=d9924bfb15be4a412c5d30ffc3c153fb65db609d6f0526759c3ece67141e5e6e"
    }
  },
  {
    "ts": null,
    "headline": "2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone",
    "summary": "Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.",
    "url": "https://finnhub.io/api/news?id=926999938b0fe33f3c1fc7c0ca1e5db52929e7393e238aee36c364dbfcb94eb1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735205400,
      "headline": "2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone",
      "id": 132164311,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.",
      "url": "https://finnhub.io/api/news?id=926999938b0fe33f3c1fc7c0ca1e5db52929e7393e238aee36c364dbfcb94eb1"
    }
  }
]